SC99 as "someone who knows much more about medicine and biotech than the world of finance," can you offer your comment for the following?

1) Is there a possibility that ( for example) drug manufacturers of SGLT2 diabetes drugs are satisfied with their own drug without adding the benefit of MACE if it does not already have the MACE benefit? Perhaps they cannot justify the additional expense and time for new clinical (BOM2) the trial, which may not generate additional revenue in the long run. Many commercials are being played these days with diabetes drugs with added MACE benefits.

2) Can ABL make it as a stand-alone drug in preventing Major Adverse Cardiac Events (MACE) in high-risk cardiovascular disease patients with type 2 Diabetes Mellitus, with the added benefit, of reducing hospitalization for heart failure?

Koo